Hyperpigmentation postinflammatory L81.0

Localized or disseminated but also generalized or systematized hyperpigmentation due to increased melanocyte activity, which is often associated with pigment incontinence. Such hyperpigmentations are observed during or after healing of inflammatory dermatoses (e.g. lichen planus).

Classification of inflammatory skin diseases associated with hyperpigmentation (alphabetical order):

• Drug exanthema
• Erythema dyschromicum perstans
• hyperpigmentation, caloric
• hyperpigmentation, flagellate
• Incontinentia pigmenti, Bloch-Sulzberger type
• lichen planus
• melanodermatitis toxica
• Melanoerythroderma
• Melanosis, Riehl-Melanosis
• pemphigus vulgaris
• Phototoxic dermatitis
• Poikiloderma congenital (e.g. Bloom syndrome, e.g. Rothmund-Thomson syndrome)
• Purpura pigmentosa progressive
• Zoster

If necessary, cosmetic coverage, e.g. with Dermacolor. Consistent UV protection is also crucial (UVB and UVA).tyrosinase inhibitors form the basis of therapy for post-inflammatory hyperpigmentation, with hydroquinone being the most important active ingredient. Alternatively, mequinol, retinoids and azelaic acid can be used, sometimes in combination with a short-term topical corticosteroid. Chemical peels and laser therapies can be effective, but should only be used with caution due to the risk of additional hyperpigmentation. A new, very potent treatment option is stabilized topical cysteamine. Simultaneous treatment of the underlying disease can prevent consecutive melanocyte activation.